---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-314745"
form_type: "8-K"
ticker: "TPST"
cik: "0001544227"
company_name: "Tempest Therapeutics, Inc."
filed_at: "2022-12-29T23:59:59+00:00"
generated_at: "2026-06-20T21:52:43.710775+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tempest Therapeutics Amends Loan Agreement with Oxford Finance, Adds Borrowers and Extends Interest-Only Period

## Summary
- Tempest Therapeutics entered into a First Amendment to Loan and Security Agreement with Oxford Finance LLC on Dec 23, 2022.
- The amendment adds Tempest Therapeutics and Millendo Therapeutics US as co-borrowers under the loan.
- Interest-only repayment period extended through Dec 31, 2023, with possible extension to June 30, 2024.
- Lender permitted a one-time prepayment of $5.0 million by Dec 28, 2022.
- Minimum liquidity covenant of $5.0 million in collateral accounts required.

## SEC filing metadata
- accession: 0001193125-22-314745
- form_type: 8-K
- ticker: TPST
- cik: 0001544227
- company_name: Tempest Therapeutics, Inc.
- filed_at: 2022-12-29T23:59:59+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1544227/000119312522314745/0001193125-22-314745-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1544227/000119312522314745/d411465d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-314745
- JSON: https://secwatch.observer/filing/0001193125-22-314745.json
- Plain text: https://secwatch.observer/filing/0001193125-22-314745.txt

## Key facts
- Material Agreements
  Tempest Therapeutics, Inc. amended First Amendment to Loan and Security Agreement with Oxford Finance LLC, as collateral agent, and certain additional lenders valued at $5.0 million (effective 2022-12-23).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: Oxford Finance LLC, as collateral agent, and certain additional lenders
  - Value: $5.0 million
  - Effective: 2022-12-23
  source text: On December 23, 2022, Tempest Therapeutics, Inc. (the “ Company ”) entered into a First Amendment to Loan and Security Agreement (the “ LSA Amendment ”), which modified that certain Loan and Security Agreement dated as of January 15, 2021 (as amended, restated, supplemented or otherwise modified from time to time, the “ Loan Agreement ”) by and among TempestTX, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“ TempestTX ”), Oxford Finance LLC (the “ Lender ”), as collateral agent, and certain additional lenders party thereto from time to time. Pursuant to the LSA Amendment, (i) each of the Company and Millendo Therapeutics US, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“ Millendo ”), were joined as co-borrowers under the Loan Agreement, (ii) the interest-only repayment period was extended through December 31, 2023 (which interest-only period may be further extended through June 30, 2024 under certain circumstances), and (iii) a sec
  evidence_url: https://www.sec.gov/Archives/edgar/data/1544227/000119312522314745/0001193125-22-314745-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.